TriSalus Life Sciences (TLSI) Change in Receivables (2022 - 2026)

TriSalus Life Sciences' Change in Receivables history runs 5 years deep, the most recent figure standing at -$1.3 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 452.73% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was -$23000.0, a 101.69% decrease from a year earlier, with the FY2025 full-year figure at $1.6 million, down 4.94% from the prior year.
• Change in Receivables slipped to -$1.3 million in Q1 2026 per TLSI's latest filing, from $1.6 million in the prior quarter.
• Across five years, Change in Receivables topped out at $1.6 million in Q4 2025 and bottomed at -$1.3 million in Q1 2026.
• The 5-year median for Change in Receivables is $363500.0 (2024), against an average of $236071.4.
• Across the five-year window, Change in Receivables jumped 1965.71% in 2024 and slumped 452.73% in 2026, its largest moves.
• Year by year, Change in Receivables stood at -$736000.0 in 2022, then jumped by 168.21% to $502000.0 in 2023, then fell by 28.09% to $361000.0 in 2024, then surged by 340.72% to $1.6 million in 2025, then slumped by 181.14% to -$1.3 million in 2026.
• Per Business Quant, the three latest TLSI Change in Receivables figures stand at -$1.3 million (Q1 2026), $1.6 million (Q4 2025), and -$497000.0 (Q3 2025).